GeoVax Labs (GOVX) Cash from Financing Activities (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly Cash from Financing Activities of $3.0 million for Q4 2025, down 34.91% year-over-year from $4.7 million in Q4 2024, and down 62.61% quarter-over-quarter from $8.1 million in Q3 2025.
GeoVax Labs (GOVX) Cash from Financing Activities (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Cash from Financing Activities for 15 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 34.91% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $19.1 million (down 19.66% YoY), while the FY2025 annual figure was $19.1 million, down 19.66% from the prior year.
- Cash from Financing Activities retreated to $3.0 million in Q4 2025 per GOVX's latest filing, from $8.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $18.5 million in Q2 2022 and bottomed at -$25801.0 in Q2 2021.
- Historically, Cash from Financing Activities has averaged $6.8 million across 5 years, with a median of $6.1 million in 2022.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities sank 102.44% — and 2022, when it jumped 71796.88%.
- GeoVax Labs' Cash from Financing Activities stood at $230000.0 in 2021, then soared by 3215.45% to $7.6 million in 2022, then tumbled by 46.73% to $4.1 million in 2023, then gained by 14.91% to $4.7 million in 2024, then tumbled by 34.91% to $3.0 million in 2025.
- Business Quant data shows GOVX's Cash from Financing Activities at $3.0 million in Q4 2025, $8.1 million in Q3 2025, and $209.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.04 Mn |
| Dec 31, 2025 | 3.04 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 209.00 |
| Jun 30, 2025 | 209.00 |
| Mar 31, 2025 | 7.91 Mn |
| Mar 31, 2025 | 7.91 Mn |
| Dec 31, 2024 | 4.67 Mn |
| Dec 31, 2024 | 4.67 Mn |
| Sep 30, 2024 | 16.35 Mn |
| Sep 30, 2024 | 16.35 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Dec 31, 2023 | 4.06 Mn |
| Dec 31, 2023 | 4.06 Mn |
| Sep 30, 2022 | 7.63 Mn |
| Sep 30, 2022 | 7.63 Mn |
| Jun 30, 2022 | 18.50 Mn |
| Jun 30, 2022 | 18.50 Mn |